Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henning Olbrich

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Expert Opinion on Emerging Drugs|August 29, 2025
Emerging drugs for the treatment of bullous pemphigoid: what's new on the horizon?Henning Olbrich, Christian D Sadik
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 26, 2023
Seltene Form der Epidermolysis bullosa simplex mit homozygoter Mutation im Gen EXPH5Henning Olbrich, Judith Fischer, Iakov Shimanovich
Virus Genes|July 27, 2017
Reconstructing the immune system with lentiviral vectorsHenning Olbrich, Constanze Slabik, Renata Stripecke
Expert Opinion on Investigational Drugs|August 1, 2023
Autoimmune blistering diseases: promising agents in clinical trialsHenning Olbrich, Christian D Sadik, Enno Schmidt
Clinical and Experimental Dermatology|July 18, 2023
Epidermolysis bullosa simplex caused by a rare homozygous mutation in the EXPH5 geneHenning Olbrich, Alrun Hotz, Judith Fischer, et al.
Frontiers in Pharmacology|February 26, 2026
Impact of non-steroidal anti-inflammatory drugs on malignant transformation in oral lichen planus: insights from a real-world cohort studyChristian Seebauer, Ralf Ludwig, Peter Sieg, et al.
Pharmacological Research|July 13, 2025
HPV vaccination and malignancy risks beyond cervical cancer: A retrospective global cohort studyChristian Seebauer, Mohamed Faluogy, Peter Sieg, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 6, 2026
Second-generation H1-antihistamines do not alter dementia risk in type 2 inflammatory diseases: A target trial emulation using real-world dataHenning Olbrich, Pavel Kolkhir, Torsten Zuberbier, et al.
Acta Dermato-Venereologica|July 6, 2026
Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort StudyPhilip Curman, Henning Olbrich, Khalaf Kridin, et al.
Frontiers in Medicine|April 18, 2025
Increased risk of skin cancers in mucous membrane pemphigoid: a large-scale matched cohort study of 117 million US individualsAmar Nouri, Henning Olbrich, Enno Schmidt, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Expert Opinion on Emerging Drugs|August 29, 2025
Emerging drugs for the treatment of bullous pemphigoid: what's new on the horizon?Henning Olbrich, Christian D Sadik
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 26, 2023
Seltene Form der Epidermolysis bullosa simplex mit homozygoter Mutation im Gen EXPH5Henning Olbrich, Judith Fischer, Iakov Shimanovich
Virus Genes|July 27, 2017
Reconstructing the immune system with lentiviral vectorsHenning Olbrich, Constanze Slabik, Renata Stripecke
Expert Opinion on Investigational Drugs|August 1, 2023
Autoimmune blistering diseases: promising agents in clinical trialsHenning Olbrich, Christian D Sadik, Enno Schmidt
Clinical and Experimental Dermatology|July 18, 2023
Epidermolysis bullosa simplex caused by a rare homozygous mutation in the EXPH5 geneHenning Olbrich, Alrun Hotz, Judith Fischer, et al.
Frontiers in Pharmacology|February 26, 2026
Impact of non-steroidal anti-inflammatory drugs on malignant transformation in oral lichen planus: insights from a real-world cohort studyChristian Seebauer, Ralf Ludwig, Peter Sieg, et al.
Pharmacological Research|July 13, 2025
HPV vaccination and malignancy risks beyond cervical cancer: A retrospective global cohort studyChristian Seebauer, Mohamed Faluogy, Peter Sieg, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 6, 2026
Second-generation H1-antihistamines do not alter dementia risk in type 2 inflammatory diseases: A target trial emulation using real-world dataHenning Olbrich, Pavel Kolkhir, Torsten Zuberbier, et al.
Acta Dermato-Venereologica|July 6, 2026
Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort StudyPhilip Curman, Henning Olbrich, Khalaf Kridin, et al.
Frontiers in Medicine|April 18, 2025
Increased risk of skin cancers in mucous membrane pemphigoid: a large-scale matched cohort study of 117 million US individualsAmar Nouri, Henning Olbrich, Enno Schmidt, et al.
Pageof 5